Skip to search formSkip to main contentSkip to account menu

Anti-CD38 Monoclonal Antibody MOR03087

Known as: MOR03087 
A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Anti-CD38 monoclonal… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

MOR202
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Emerging antibodies for the treatment of multiple myeloma
ABSTRACT Introduction: Monoclonal antibodies mark the beginning of a new era in the context of multiple myeloma (MM) treatment… 
2015
2015
A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).
8574 Background: MOR202 is a HuCAL-derived fully human IgG1 anti-CD38 antibody, with high efficacy in preclinical models of MM… 
2015
2015
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma
Background: CD38 is a type II transmembrane glycoprotein that is expressed at high levels on multiple myeloma cells. MOR202 is a… 
2015
2015
A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma
2012
2012
Companies wager high on CD38-targeting drugs for blood cancer
On 30 August, the Danish biotech GenMab signed a $1.1 billion deal turning over licensing rights for its experimental blood… 
2012
2012
Despite quintuple disappointments, Lilly still charms investors
On 30 August, the Danish biotech GenMab signed a $1.1 billion deal turning over licensing rights for its experimental blood… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)